240 related articles for article (PubMed ID: 24302718)
1. Coherence between cellular responses and in vitro splicing inhibition for the anti-tumor drug pladienolide B and its analogs.
Effenberger KA; Anderson DD; Bray WM; Prichard BE; Ma N; Adams MS; Ghosh AK; Jurica MS
J Biol Chem; 2014 Jan; 289(4):1938-47. PubMed ID: 24302718
[TBL] [Abstract][Full Text] [Related]
2. Total synthesis of 6-deoxypladienolide D and Assessment of Splicing Inhibitory Activity in a Mutant SF3B1 cancer cell line.
Arai K; Buonamici S; Chan B; Corson L; Endo A; Gerard B; Hao MH; Karr C; Kira K; Lee L; Liu X; Lowe JT; Luo T; Marcaurelle LA; Mizui Y; Nevalainen M; O'Shea MW; Park ES; Perino SA; Prajapati S; Shan M; Smith PG; Tivitmahaisoon P; Wang JY; Warmuth M; Wu KM; Yu L; Zhang H; Zheng GZ; Keaney GF
Org Lett; 2014 Nov; 16(21):5560-3. PubMed ID: 25376106
[TBL] [Abstract][Full Text] [Related]
3. Chemical Inhibition of Pre-mRNA Splicing in Living Saccharomyces cerevisiae.
Hansen SR; Nikolai BJ; Spreacker PJ; Carrocci TJ; Hoskins AA
Cell Chem Biol; 2019 Mar; 26(3):443-448.e3. PubMed ID: 30639260
[TBL] [Abstract][Full Text] [Related]
4. Herboxidiene Features That Mediate Conformation-Dependent SF3B1 Interactions to Inhibit Splicing.
Gamboa Lopez A; Allu SR; Mendez P; Chandrashekar Reddy G; Maul-Newby HM; Ghosh AK; Jurica MS
ACS Chem Biol; 2021 Mar; 16(3):520-528. PubMed ID: 33617218
[TBL] [Abstract][Full Text] [Related]
5. Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA.
Kaida D; Motoyoshi H; Tashiro E; Nojima T; Hagiwara M; Ishigami K; Watanabe H; Kitahara T; Yoshida T; Nakajima H; Tani T; Horinouchi S; Yoshida M
Nat Chem Biol; 2007 Sep; 3(9):576-83. PubMed ID: 17643111
[TBL] [Abstract][Full Text] [Related]
6. Identification of SAP155 as the target of GEX1A (Herboxidiene), an antitumor natural product.
Hasegawa M; Miura T; Kuzuya K; Inoue A; Won Ki S; Horinouchi S; Yoshida T; Kunoh T; Koseki K; Mino K; Sasaki R; Yoshida M; Mizukami T
ACS Chem Biol; 2011 Mar; 6(3):229-33. PubMed ID: 21138297
[TBL] [Abstract][Full Text] [Related]
7. Biological validation that SF3b is a target of the antitumor macrolide pladienolide.
Yokoi A; Kotake Y; Takahashi K; Kadowaki T; Matsumoto Y; Minoshima Y; Sugi NH; Sagane K; Hamaguchi M; Iwata M; Mizui Y
FEBS J; 2011 Dec; 278(24):4870-80. PubMed ID: 21981285
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of SF3b1 by pladienolide B evokes cycle arrest, apoptosis induction and p73 splicing in human cervical carcinoma cells.
Zhang Q; Di C; Yan J; Wang F; Qu T; Wang Y; Chen Y; Zhang X; Liu Y; Yang H; Zhang H
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):1273-1280. PubMed ID: 30963795
[TBL] [Abstract][Full Text] [Related]
9. Structural Basis of Splicing Modulation by Antitumor Macrolide Compounds.
Cretu C; Agrawal AA; Cook A; Will CL; Fekkes P; Smith PG; Lührmann R; Larsen N; Buonamici S; Pena V
Mol Cell; 2018 Apr; 70(2):265-273.e8. PubMed ID: 29656923
[TBL] [Abstract][Full Text] [Related]
10. SF3B1 mutations constitute a novel therapeutic target in breast cancer.
Maguire SL; Leonidou A; Wai P; Marchiò C; Ng CK; Sapino A; Salomon AV; Reis-Filho JS; Weigelt B; Natrajan RC
J Pathol; 2015 Mar; 235(4):571-80. PubMed ID: 25424858
[TBL] [Abstract][Full Text] [Related]
11. Splicing modulators act at the branch point adenosine binding pocket defined by the PHF5A-SF3b complex.
Teng T; Tsai JH; Puyang X; Seiler M; Peng S; Prajapati S; Aird D; Buonamici S; Caleb B; Chan B; Corson L; Feala J; Fekkes P; Gerard B; Karr C; Korpal M; Liu X; T Lowe J; Mizui Y; Palacino J; Park E; Smith PG; Subramanian V; Wu ZJ; Zou J; Yu L; Chicas A; Warmuth M; Larsen N; Zhu P
Nat Commun; 2017 May; 8():15522. PubMed ID: 28541300
[TBL] [Abstract][Full Text] [Related]
12. Interchangeable SF3B1 inhibitors interfere with pre-mRNA splicing at multiple stages.
Effenberger KA; Urabe VK; Prichard BE; Ghosh AK; Jurica MS
RNA; 2016 Mar; 22(3):350-9. PubMed ID: 26742993
[TBL] [Abstract][Full Text] [Related]
13. Pre-mRNA splicing-modulatory pharmacophores: the total synthesis of herboxidiene, a pladienolide-herboxidiene hybrid analog and related derivatives.
Lagisetti C; Yermolina MV; Sharma LK; Palacios G; Prigaro BJ; Webb TR
ACS Chem Biol; 2014 Mar; 9(3):643-8. PubMed ID: 24377313
[TBL] [Abstract][Full Text] [Related]
14. Targeting the spliceosome in chronic lymphocytic leukemia with the macrolides FD-895 and pladienolide-B.
Kashyap MK; Kumar D; Villa R; La Clair JJ; Benner C; Sasik R; Jones H; Ghia EM; Rassenti LZ; Kipps TJ; Burkart MD; Castro JE
Haematologica; 2015 Jul; 100(7):945-54. PubMed ID: 25862704
[TBL] [Abstract][Full Text] [Related]
15. Spliceostatin A interaction with SF3B limits U1 snRNP availability and causes premature cleavage and polyadenylation.
Yoshimoto R; Chhipi-Shrestha JK; Schneider-Poetsch T; Furuno M; Burroughs AM; Noma S; Suzuki H; Hayashizaki Y; Mayeda A; Nakagawa S; Kaida D; Iwasaki S; Yoshida M
Cell Chem Biol; 2021 Sep; 28(9):1356-1365.e4. PubMed ID: 33784500
[TBL] [Abstract][Full Text] [Related]
16. Reduced fidelity of branch point recognition and alternative splicing induced by the anti-tumor drug spliceostatin A.
Corrionero A; Miñana B; Valcárcel J
Genes Dev; 2011 Mar; 25(5):445-59. PubMed ID: 21363963
[TBL] [Abstract][Full Text] [Related]
17. Splicing factor SF3b as a target of the antitumor natural product pladienolide.
Kotake Y; Sagane K; Owa T; Mimori-Kiyosue Y; Shimizu H; Uesugi M; Ishihama Y; Iwata M; Mizui Y
Nat Chem Biol; 2007 Sep; 3(9):570-5. PubMed ID: 17643112
[TBL] [Abstract][Full Text] [Related]
18. Regulation of HPV16 E6 and MCL1 by SF3B1 inhibitor in head and neck cancer cells.
Gao Y; Trivedi S; Ferris RL; Koide K
Sci Rep; 2014 Aug; 4():6098. PubMed ID: 25139387
[TBL] [Abstract][Full Text] [Related]
19. Structural requirements for the antiproliferative activity of pre-mRNA splicing inhibitor FR901464.
Osman S; Albert BJ; Wang Y; Li M; Czaicki NL; Koide K
Chemistry; 2011 Jan; 17(3):895-904. PubMed ID: 21226105
[TBL] [Abstract][Full Text] [Related]
20. Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma.
Sciarrillo R; Wojtuszkiewicz A; El Hassouni B; Funel N; Gandellini P; Lagerweij T; Buonamici S; Blijlevens M; Zeeuw van der Laan EA; Zaffaroni N; Deraco M; Kusamura S; Würdinger T; Peters GJ; Molthoff CFM; Jansen G; Kaspers GJL; Cloos J; Giovannetti E
EBioMedicine; 2019 Jan; 39():215-225. PubMed ID: 30581150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
